ArticleCancers2022

Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma.

Shinji Unome et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.